Comprehensive Report on ILUVIEN for Autoimmune Uveitis Reveals Market Size, Insights, and Forecast to 2032 in Key European Markets [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Alimera Sciences, Inc. (ALIM)
Last alimera sciences, inc. earnings: 4/29 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.alimerasciences.com/investor-relations
Company Research
Source: Yahoo! Finance
A report furnishing thorough insights into the use of ILUVIEN for autoimmune uveitis across Germany, France, Italy, Spain, and the United Kingdom has been released. ILUVIEN, developed by Alimera Sciences, is an intravitreal implant designed to release a corticosteroid into the eye for up to 3 years, providing a sustained treatment alternative for chronic or recurrent uveitis affecting the posterior segment of the eye. Market Forecast and Clinical Assessment The future market scenario for ILUVIEN is expected to transform owing to continued research and increased healthcare expenditure. Projected market data, extending from 2024 to 2032, indicates a potential increase in the utilization and sales of ILUVIEN, bolstering its position in the market. In addition, the report includes an in-depth clinical trial assessment covering aspects such as trial status, conditions, interventions, and timelines, facilitating a comprehensive understanding of ILUVILUEN's development and efficacy. R
Show less
Read more
Impact Snapshot
Event Time:
ALIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALIM alerts
High impacting Alimera Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
ALIM
News
- Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, ALIM, INFN on Behalf of ShareholdersPR Newswire
- ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIMBusiness Wire
ALIM
Earnings
- 8/6/24 - Miss
ALIM
Sec Filings
- 8/8/24 - Form DEFM14A
- 8/7/24 - Form 10-Q
- 8/6/24 - Form 425
- ALIM's page on the SEC website